Research has proposed that inhibition of the PI3K/AKT signaling pathway can play antitumor effect in a huge number of human cancers, such as leukemia, breast cancer, bladder cancer, and ovarian cancer [26–29]. This evidence concerns the gene AKT1 and ovarian carcinoma.